GALT (Galectin Therapeutics) Total Liabilities: $146.00 Mil (As of Mar. 2026)


GALT Galectin Therapeutics Inc GALT
16 GF Score
Price $4.97
! 5 Warning Signs
View Full Analysis

What is Galectin Therapeutics Total Liabilities?

Galectin Therapeutics GALT 16 Total Liabilities is $146.00 Mil as of Mar. 2026. GuruFocus rates GALT with a GF Score™ of 16/100. The stock has 5 warning signs investors should review.

Galectin Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $146.00 Mil.

Galectin Therapeutics's quarterly Total Liabilities increased from Sep. 2025 ($138.17 Mil) to Dec. 2025 ($145.73 Mil) and increased from Dec. 2025 ($145.73 Mil) to Mar. 2026 ($146.00 Mil).

Galectin Therapeutics's annual Total Liabilities increased from Dec. 2023 ($88.44 Mil) to Dec. 2024 ($120.57 Mil) and increased from Dec. 2024 ($120.57 Mil) to Dec. 2025 ($145.73 Mil).

Galectin Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Galectin Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galectin Therapeutics Total Liabilities Chart

Galectin Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.21 53.48 88.44 120.57 145.73

Galectin Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 121.79 132.77 138.17 145.73 146.00
GALT
16GF Score
Galectin Therapeutics Inc GALT
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galectin Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Galectin Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=8.03+(133.735+3.962
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=145.73

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=19.532--126.195
=145.73

Galectin Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7.307+(135.71+2.979
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=146.00

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=15.759--130.237
=146.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $146.00 Mil mean?
Galectin Therapeutics (GALT) has a Total Liabilities of $146.00 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Galectin Therapeutics and its competitors.
Is Galectin Therapeutics' Total Liabilities too high?
Galectin Therapeutics' current Total Liabilities is $146.00 Mil. Overall, Galectin Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Galectin Therapeutics' Total Liabilities compare to PALI and IRD?
Galectin Therapeutics' Total Liabilities of $146.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Galectin Therapeutics and its competitors. Galectin Therapeutics's current Total Liabilities is $146.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galectin Therapeutics stock overvalued right now?
Galectin Therapeutics (GALT) has a current Total Liabilities of $146.00 Mil. The current Total Liabilities is $146.00 Mil. Galectin Therapeutics' overall GF Score™ is 16/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Galectin Therapeutics (GALT), the current Total Liabilities is $146.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galectin Therapeutics Business Description

Other Exchanges PHPN:Germany
Address 4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
16GF Score

Get the complete analysis for GALT

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.97
Price